For Immediate Release <\/p>\n
Chicago, IL \u2013 June 24, 2026 \u2013 Today, Zacks Investment Ideas feature highlights iShares Biotechnology ETF IBB, Novartis NVS, Pfizer PFE and Eli Lilly\u2019s LLY.<\/p>\n
Biotech’s Silent Resurgence (5-Year Base Breakout) <\/p>\n
Starting in early 2021, the notoriously difficult-to-invest-in biotech sector suffered one of its most brutal bear markets in history. The iShares Biotechnology ETF, a proxy for the Nasdaq Biotechnology Index and pure-play biotech companies, slumped 33%, failing to notch fresh highs for more than four years. While a 33% drawdown may not seem like much in a vacuum, such a drawdown has far more meaning when compared to the S&P 500 Index, which rose more than 60% over the same period.<\/p>\n
While U.S. markets have enjoyed a multi-year rally mainly driven by big tech, while biotech has suffered a volatile, choppy, and prolonged sell-off. Although large-cap, cash-rich, mega-cap biotech stocks saw less pain, numerous clinical-stage, speculative biotech stocks loss 50% of their value or more. What caused the carnage?<\/p>\n
\u00b7 Higher Interest Rates: Early-stage biotech companies often must rely on borrowed money for a decade or more. Interest rate hikes made borrowing more expensive for these companies.<\/p>\n
\u00b7 Post-COVID Hype Died: While biotech companies were the poster-child of the COVID-19 era on Wall Street, \u201ctourist\u201d investors rushed for the exits afterward, causing selling pressure.<\/p>\n
\u00b7 Regulatory Red Tape: The Biden Administration\u2019s Federal Trade Commission (FTC) took a very \u201chawkish\u201d approach to mergers and acquisitions (M&A). M&A is the lifeblood of the biotech sector. Additionally, the Inflation Reduction Act (IRA) introduced government negotiations for Medicare, chilling investment in certain therapeutic areas.<\/p>\n
Has Biotech Turned the Corner? <\/p>\n
The biotech sector is showing promising signs that it has turned the corner. Often, the first sign of a turnaround shows its hand in price, which is why legendary investor Stanley Druckenmiller prefers to \u201cinvest, then investigate.\u201d That\u2019s exactly what\u2019s occurring in biotech. The IBB is exhibiting extraordinary relative strength. For instance, the Nasdaq dropped nearly 1,000 points on Tuesday. However, IBB bucked the weakness and gained nearly a percent for the session.<\/p>\n
Meanwhile, the longer timeframe also shows promising relative strength. While many tech stocks have plunged off recent highs, IBB is making new highs and is on the cusp of breaking out of a massive 5-year base. As the old Wall Street adage goes, \u201cThe longer the base, the higher in space!\u201d<\/p>\n
Story Continues <\/p>\n
5 Reasons to Own Biotech <\/p>\n
Biotech\u2019s bull case goes far beyond its price action. Below are 5 reasons to own the sector:<\/p>\n
AI Will Drive Discovery, Reduce Costs <\/p>\n
Discovering a drug and passing a clinical trial can result in years of research and development (R&D) expenses. However, that is likely to change with the advent of high-powered AI models. Predictive AI models and advanced computing infrastructure will dramatically reduce R&D expenses and shave off years of R&D time.<\/p>\n
M&A & Reduced Red Tape <\/p>\n
Between now and the end of the decade, the biotech industry faces a tsunami of patent expirations on blockbuster drugs. For instance, the Novartis heart failure blockbuster drug recently lost key patents, and the Pfizer breast cancer drug will soon. These massive revenue hits will cause big tech companies to acquire clinical-stage biotech companies to fill the void. Additionally, a less hawkish FTC means that more acquisitions are likely to be given the green light.<\/p>\n
The Coming GLP-1 Supercycle <\/p>\n
Breakthrough GLP-1 drugs likeEli Lilly\u2019s \u201cMounjaro\u201d are likely to lead to a biotech super cycle. In fact, GLP-1s are the closest thing the biotech industry has produced to a wonder drug. For instance, GLP-1s have proven to dramatically reduce obesity, inflammation, and the risk of cardiovascular-related death.<\/p>\n
Rock-Bottom Valuations <\/p>\n
Biotech\u2019s multi-year bear market has resulted in poor sentiment and rock-bottom valuations \u2013 a recipe for a bull market. For example, Pfizer\u2019s P\/E is currently hovering near an all-time low.<\/p>\n
Diversification & Defense <\/p>\n
Wall Street\u2019s AI frenzy has likely led to overconcentration in the tech sector. As a result, money managers may look to diversify into biotech and defensive healthcare names.<\/p>\n
Bottom Line <\/p>\n
With the regulatory friction of a hawkish FTC easing, massive big-pharma cash piles searching for pipeline replacements, and game-changing AI efficiencies coming online, the biotech sector\u2019s fundamentals have fundamentally transformed.<\/p>\n
Why Haven’t You Looked at Zacks’ Top Stocks? <\/p>\n
Since 2000, our top stock-picking strategies have blown away the S&P’s +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year.<\/p>\n
Today you can access their live picks without cost or obligation.<\/p>\n
See Stocks Free >><\/p>\n
Media Contact<\/p>\n
Zacks Investment Research<\/p>\n
800-767-3771 ext. 9339<\/p>\n
support@zacks.com<\/p>\n
https:\/\/www.zacks.com<\/p>\n
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed\u00a0that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and\u00a0is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https:\/\/www.zacks.com\/performance\u00a0for information about the performance numbers displayed in this press release.<\/p>\n
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report<\/a><\/p>\n Novartis AG (NVS) : Free Stock Analysis Report<\/a><\/p>\n Pfizer Inc. (PFE) : Free Stock Analysis Report<\/a><\/p>\n Eli Lilly and Company (LLY) : Free Stock Analysis Report<\/a><\/p>\n iShares Biotechnology ETF (IBB): ETF Research Reports<\/a><\/p>\n This article originally published on Zacks Investment Research (zacks.com).<\/a><\/p>\n